Zenas BioPharma, Inc. (ZBIO)
ZBIO moved a median of -0.25% 30 minutes after news, and -0.01% by the close. How ZBIO actually reacts to news — the realized, point-in-time move the market made, measured across 943 labeled events over the last three years with zero look-ahead.
ZBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 894 |
| 30-min | -0.25% | 47% | 934 |
| 60-min | -0.11% | 47% | 938 |
| to close | -0.01% | 50% | 934 |
| Middle 50% of ZBIO reactions | -2.06% to +1.43% |
|---|---|
| Median reaction (30-min) | -0.25% |
| Measured reactions | 943 |
Half of all Zenas BioPharma, Inc. news events land between -2.06% and +1.43% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ZBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 19 | -2.15% | 47% | -0.39% |
| Rating reiterations | 50 | +0.76% | 72% | +0.64% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ZBIO ranks against every other measured name →
That’s how ZBIO usually reacts — get an email when it moves on news →Email me when ZBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ZBIO's baseline. Nothing else.
Recent ZBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 | Press release | GlobeNewswire | +0.83% | +1.54% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.02% | +2.94% | |
| Form S-3ASR Zenas BioPharma, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -0.16% | +2.94% | |
| Form S-8 Zenas BioPharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.16% | +2.94% | |
| Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event | Press release | GlobeNewswire | -1.06% | +1.23% | |
| Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences | Press release | GlobeNewswire | +0.00% | +0.67% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.04% | -4.73% | |
| Form 10-Q Zenas BioPharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.76% | -3.92% | |
| Form 8-K Zenas BioPharma, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -2.76% | -3.92% | |
| Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.76% | -3.92% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.24% | +3.44% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.92% | +4.49% | |
| Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | Press release | GlobeNewswire | +1.24% | +11.36% | |
| Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | Press release | GlobeNewswire | -0.29% | +0.64% | |
| Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | Press release | GlobeNewswire | -1.20% | +1.53% | |
| Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | Press release | GlobeNewswire | -3.74% | -0.45% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -3.74% | -0.45% | |
| Form 10-Q Zenas BioPharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.66% | +1.68% | |
| Form 8-K Zenas BioPharma, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +1.68% | |
| Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | Press release | GlobeNewswire | -0.66% | +1.68% | |
| Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.66% | +1.68% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.43% | -4.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.05% | +0.50% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.72% | +3.39% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.10% | +4.63% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.24% | +4.46% | |
| Form 8-K Zenas BioPharma, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -2.50% | -0.24% | |
| Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million | Press release | GlobeNewswire | -3.00% | -5.75% | |
| Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock | Press release | GlobeNewswire | -3.00% | -5.75% | |
| Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | -1.31% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.71% | -7.98% | |
| Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.79% | +1.92% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.31% | +2.40% | |
| Form 10-K Zenas BioPharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.21% | -0.51% | |
| Form 8-K Zenas BioPharma, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -0.51% | |
| Form ARS Zenas BioPharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.21% | -0.51% | |
| Form DEF 14A Zenas BioPharma, Inc. For: May 11 | SEC filing · Form DEF | SEC EDGAR | -0.21% | -0.51% | |
| Form DEFA14A Zenas BioPharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.21% | -0.51% | |
| Form S-8 Zenas BioPharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.21% | -0.51% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.06% | +0.09% | |
| Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.21% | -0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.21% | -0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.37% | +0.33% | |
| Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.52% | +0.62% | |
| Form 8-K Zenas BioPharma, Inc. For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -5.72% | -8.23% | |
| Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 | Press release | GlobeNewswire | -1.03% | +0.90% | |
| Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +2.73% | -2.59% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -1.58% | -0.98% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.82% | -0.82% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.27% | -2.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ZBIO section they belong to.
Where else ZBIO is measured.
ZBIO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Zenas BioPharma, Inc.'s median reaction calculated?
Every labeled ZBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 943 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of ZBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ZBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.